A retrospective study to assess health-related quality of life in midgut neuroendocrine tumors patients undergoing peptide receptor radionuclide therapy
Latest Information Update: 05 Nov 2020
Price :
$35 *
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 05 Nov 2020 New trial record